Compositions and methods for treating and preventing;infections
First Claim
Patent Images
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO:
- 2, 3, and 4, respectively, and a light chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO;
7, 8, and 9, respectively, wherein the monoclonal antibody specifically binds Staphylococcus aureus protein A (SpA) with a KD of less than 1×
10−
10 M via its Fab region paratope, wherein the monoclonal antibody is able to displace human IgG immunoglobulins bound to SpA on Staphylococcus aureus bacteria via their Fc regions.
2 Assignments
0 Petitions
Accused Products
Abstract
Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.
30 Citations
8 Claims
-
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO:
- 2, 3, and 4, respectively, and a light chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO;
7, 8, and 9, respectively, wherein the monoclonal antibody specifically binds Staphylococcus aureus protein A (SpA) with a KD of less than 1×
10−
10 M via its Fab region paratope, wherein the monoclonal antibody is able to displace human IgG immunoglobulins bound to SpA on Staphylococcus aureus bacteria via their Fc regions. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- 2, 3, and 4, respectively, and a light chain variable domain comprising a CDR1, CDR2, and CDR3 of SEQ ID NO;
Specification